Impact of treatment characteristics on response of different breast cancer phenotypes: Pooled analysis of the German neo-adjuvant chemotherapy trials

Breast Cancer Research and Treatment

Volumn 125, Issue 1, 2011, Pages 145-156

  Von Minckwitz, Gunter ^a   Untch, Michael ^b   Nüesch, Eveline ^c   Loibl, Sibylle ^a   Kaufmann, Manfred ^d   Kümmel, Sherko ^e   Fasching, Peter A ^f   Eiermann, Wolfgang ^g   Blohmer, Jens Uwe ^h   Costa, Serban Dan ⁱ   Mehta, Keyur ^a   Hilfrich, Jörn ^j   Jackisch, Christian ^k   Gerber, Bernd ^l   Du Bois, Andreas ^m   Huober, Jens ⁿ   Hanusch, Claus ^g   Konecny, Gottfried ^o   Fett, Werner ^p   Stickeler, Elmar ^q   Harbeck, Nadia ^r   Müller, Volkmar ^s   Jüni, Peter ^c   more..

^a C/o GBG Forschungs GmbH ^*  (Germany)

^b Helios Klinikum   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Klinikum Zum Roten Kreuz   (Germany)

^h MARTIN LUTHER KRANKENHAUS   (Germany)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^j Henrietten Stiftung   (Germany)

^k Klinikum Offenbach GmbH   (Germany)

^l ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^m Horst Schmidt Klinik   (Germany)

ⁿ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p Hämato Onkologische Praxis   (Germany)

^q UNIVERSITY OF FREIBURG   (Germany)

^r UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^s UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

more..

Author keywords

Anthracyclines trastuzumab; Breast cancer; Neoadjuvant; Pooled analysis; Taxanes

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG RESPONSE; GERMANY; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 78651081149     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1228-x     Document Type: Article

References (29)

1. Peto R for the EBCTCG (2007) The worldwide overview updated (2005-6) meta-analysis of trial results. San Antonio Breast Cancer Symposium, Plenary Session Abstract 1
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) M Clarke AS Coates SC Darby, et al. 2008 Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials Lancet 371 29 40 1:STN:280:DC%2BD1c%2FhtFGqtw%3D%3D 10.1016/S0140-6736(08)60196-8 18177773 (Pubitemid 351173315)
4. National Collaborating Centre for Cancer (2009) Early and locally advanced breast cancer: diagnosis and treatment. Velindre NHS Trust, Cardiff
5. M Kaufmann GN Hortobagyi A Goldhirsch, et al. 2006 Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940 1949 10.1200/JCO.2005.02.6187 16622270 (Pubitemid 46638994)
6. JS Mieog JA van der Hage CJ van de Velde 2007 Neoadjuvant chemotherapy for operable breast cancer Br J Surg 94 1189 1200 1:STN:280: DC%2BD2srmslaktA%3D%3D 10.1002/bjs.5894 17701939 (Pubitemid 47584766)
7. D Mauri N Pavlidis JP Ioannidis 2005 Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 188 194 10.1093/jnci/dji021 15687361 (Pubitemid 40277368)
8. Y Tao A Klause A Vickers K Bae M Ellis 2005 Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials J Steroid Biochem Mol Biol 95 91 95 1:CAS:528:DC%2BD2MXntVOhurY%3D 10.1016/j.jsbmb.2005.04.017 15994076 (Pubitemid 41137298)
9. G von Minckwitz SD Costa G Raab, et al. 2001 Dose-dense doxorubicin and docetaxel with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 3506 3515
10. G von Minckwitz G Raab A Caputo, et al. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group J Clin Oncol 23 2676 2685 10.1200/JCO.2005.05.078 (Pubitemid 46179457)
11. G von Minckwitz JU Blohmer G Raab, et al. 2005 In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study Ann Oncol 16 56 63 10.1093/annonc/ mdi001 (Pubitemid 40124479)
12. G von Minckwitz S Kummel P Vogel, et al. 2008 Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study J Natl Cancer Inst 100 552 562 10.1093/jnci/djn089
13. G von Minckwitz S Kummel P Vogel, et al. 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 542 551 10.1093/jnci/djn085
14. G von Minckwitz M Rezai S Loibl, et al. 2010 Capecitabine in addition to anthracycline/taxane-based neoadjuvant treatment in patients with primary breast cancer: the phase III GeparQuattro study J Clin Oncol 28 2015 2023 10.1200/JCO.2009.23.8303
15. M Untch M Rezai S Loibl, et al. 2010 Neoadjuvant Treatment with Trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 2024 2031 1:CAS:528:DC%2BC3cXmtlSksrg%3D 10.1200/JCO.2009.23. 8451 20308670
16. M Untch V Möbus W Kuhn, et al. 2009 Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer J Clin Oncol 27 2938 2945 10.1200/JCO.2008.20.3133 19364964
17. M Untch G Konecny N Ditsch, et al. 2002 Dose dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study Proc Am Soc Clin Oncol 21 34a (abstract 133)
18. Untch M, Stoeckl D, Konencny G et al (2005) A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. San Antonio Breast Cancer Symposium (SABCS) 2005, abstract 1064
19. JR Gralow HJ Burstein W Wood, et al. 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814 819 10.1200/JCO.2007.15.3510 18258991 (Pubitemid 351265335)
20. F Cuppone E Bria P Carlini, et al. 2008 Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials Cancer 113 238 246 1:CAS:528:DC%2BD1cXpt1OrsLk%3D 10.1002/cncr.23544 18470908
21. A Gennari MP Sormani P Pronzato, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 1:CAS:528:DC%2BD1cXit1Cku7o%3D 10.1093/jnci/djm252 18159072 (Pubitemid 351767337)
22. B Dhesy-Thind KI Pritchard H Messersmith, et al. 2008 HER2/neu in systemic therapy for women with breast cancer: a systematic review Breast Cancer Res Treat 109 209 229 1:CAS:528:DC%2BD1cXlsV2ntrs%3D 10.1007/s10549-007-9656-y 17636396 (Pubitemid 351644854)
23. GG Steger R Greil R Jakesz, et al. 2009 A randomized phase III study comparing epirubicin, docetaxel and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer: first results of ABCSG-24 Eur J Cancer Suppl 7 3 10.1016/S1359-6349(09)72030-0 (abstract)
24. H Joensuu PL Kellokumpu-Lehtinen R Huovinen, et al. 2009 Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial Lancet Oncol 10 1145 1151 1:CAS:528:DC%2BD1MXhsV2lur3I 10.1016/S1470-2045(09)70307-9 19906561
25. AU Buzdar NK Ibrahim D Francis, et al. 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 1:CAS:528:DC%2BD2MXlslWntr8%3D 10.1200/JCO.2005.07.032 15738535
26. L Gianni W Eiermann V Semiglazov, et al. 2010 Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 377 384 1:CAS:528:DC%2BC3cXht12ltLk%3D 10.1016/S0140-6736(09)61964-4 20113825
27. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 1:CAS:528:DC%2BD2MXhtFansr3L 10.1056/NEJMoa052306 16236737 (Pubitemid 41464705)
28. The Synergism or Long Duration (SOLD) Study. ClinicalTrials.gov Identifier: NCT00593697
29. PERSEPHONE-duration of trastuzumab study with chemotherapy in early breast cancer: six versus twelve months. ClinicalTrials.gov Identifier: NCT00712140